ReviewVirchows Archiv : an international journal of pathology2021
Improving tumor budding reporting in colorectal cancer: a Delphi consensus study.
Review in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 62 citations in OpenAlex.
- Interobserver variability of histopathological assessment in pT1 colorectal carcinoma.Histopathology · 2026Article
- Assessing Tumour Budding in Lung Squamous Cell Carcinoma: A Comparative Analysis of Digital Whole-Slide Imaging and Light Microscopy.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Article
- Stromal transcriptomics uncover LIF as a key effector in high tumor budding triple-negative breast cancer.Scientific reports · 2025Article
- Pathological and Clinical Significance of Tumor Budding and Its Association with Epithelial-Mesenchymal Transition in Colorectal Carcinoma: A Retrospective Observational Study.Iranian journal of medical sciences · 2025Observational
- The prognostic significance of desmoplastic reaction, tumor budding and tumor-infiltrating lymphocytes in esophageal squamous cell carcinomas.BMC gastroenterology · 2025Article
- Article
- Effective SMOTE boost with deep learning for IDC identification in whole-slide images.PloS one · 2025Article
- Tumor budding in gastric adenocarcinoma: prognostic value and association with clinicopathological markers.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Tumor Budding as a Risk Factor for Lymph Node Metastasis and Local Recurrence in pT1 Colorectal Cancer: A Systematic Review and Meta-Analysis.Gastro hep advances · 2025Review
- Colorectal Cancer: A Brief and Simplified Analysis of a Complex Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.Journal of translational medicine · 2024Article
- Immunohistochemical analysis of tumor budding in stage II colon cancer: exploring zero budding as a prognostic marker.Virchows Archiv : an international journal of pathology · 2024Article
- Differential effect of tumor budding on the benefit of adjuvant chemotherapy in stage II colorectal cancer: a retrospective observational study.Journal of gastrointestinal oncology · 2024Article
- The Relationship between Tumor Budding and Tumor Deposits in Patients with Stage III Colorectal Carcinoma.Journal of clinical medicine · 2024Article
- Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma.World journal of gastrointestinal pathophysiology · 2024Article
- Few-shot Tumor Bud Segmentation Using Generative Model in Colorectal Carcinoma.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Adapting SAM to Histopathology Images for Tumor Bud Segmentation in Colorectal Cancer.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Establish a novel tumor budding-related signature to predict prognosis and guide clinical therapy in colorectal cancer.Scientific reports · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 17 institutions in 14 countries.
Funding
Abstract
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.